{"id":23464,"date":"2022-12-21T21:07:00","date_gmt":"2022-12-21T13:07:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23464"},"modified":"2025-01-27T21:10:25","modified_gmt":"2025-01-27T13:10:25","slug":"innocare-receives-cde-approval-for-phase-ii-trial-of-orelabrutinib-combination","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23464","title":{"rendered":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination"},"content":{"rendered":"\n

China-based biopharma InnoCare Pharma (HKG: 9969<\/a>, SHA: 688428<\/a>) has announced receiving approval from China\u2019s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed\/refractory (r\/r) non-Hodgkin\u2019s lymphoma (nHL). This approval marks a significant step in InnoCare’s efforts to expand its portfolio for hematological malignancies.<\/p>\n\n\n\n

Drug Profile and Development<\/strong>
Orelabrutinib is InnoCare\u2019s in-house discovered Bruton\u2019s tyrosine kinase (BTK) inhibitor. Tafasitamab is a CD19-targeted immunotherapy originated by Xencor Inc., and in-licensed by InnoCare for Greater China development from US-based Incyte Inc. in a 2021 deal. The new trial approval means that InnoCare is expanding development activities as it aims to build a comprehensive portfolio for hematological malignancies.<\/p>\n\n\n\n

Clinical Trials and Future Prospects<\/strong>
Alongside this week\u2019s Phase II trial for the combination regimen, InnoCare is also assessing tafasitamab + lenalidomide in a registrational Phase II study for diffuse large B-cell lymphoma (DLBCL). Tafasitamab is already approved in the US (where it is branded Monjuvi) and Europe (branded Minjuvi) for DLBCL in combination with lenalidomide in patients not eligible for stem-cell transplant. InnoCare has secured early access for tafasitamab + lenalidomide via Hainan\u2019s Boao Lecheng International Medical Tourism Pilot Zone for its use in combination with lenalidomide in DLBCL.<\/p>\n\n\n\n

Orelabrutinib has already won two conditional approvals from the NMPA in China, for use in r\/r chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and r\/r mantle cell lymphoma (MCL), and approval in Singapore for r\/r MCL. NHL is a broad hematological cancer category that includes DLBCL, follicular lymphoma, and other lymphoma types. According to the source, there were 92,834 new cases of NHL and 54,351 deaths in 2020 in China.<\/p>\n\n\n\n

InnoCare is also developing orelabrutinib for a range of non-oncology diseases, including multiple sclerosis (MS), lupus, and thrombocytopenia. US major Biogen (NSDQ: BIIB) picked up global rights to develop the molecule for MS globally in a USD 930 million deal signed in July 2021. This strategic move underscores InnoCare’s commitment to innovation and addressing significant unmet medical needs in both oncology and non-oncology fields.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China\u2019s Center…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[91,16,919,107,327,920],"class_list":["post-23464","post","type-post","status-publish","format-standard","hentry","category-drug","tag-boao-lecheng-pilot-zone","tag-cancer","tag-hkg-9969","tag-immunotherapy","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"\nInnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China\u2019s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed\/refractory (r\/r) non-Hodgkin\u2019s lymphoma (nHL). This approval marks a significant step in InnoCare's efforts to expand its portfolio for hematological malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23464\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23464\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-21T13:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T13:10:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination\",\"datePublished\":\"2022-12-21T13:07:00+00:00\",\"dateModified\":\"2025-01-27T13:10:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464\"},\"wordCount\":364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Boao Lecheng pilot zone\",\"Cancer\",\"HKG: 9969\",\"Immunotherapy\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23464#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23464\",\"name\":\"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-21T13:07:00+00:00\",\"dateModified\":\"2025-01-27T13:10:25+00:00\",\"description\":\"China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China\u2019s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed\\\/refractory (r\\\/r) non-Hodgkin\u2019s lymphoma (nHL). This approval marks a significant step in InnoCare's efforts to expand its portfolio for hematological malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23464\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23464#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination - Insight, China's Pharmaceutical Industry","description":"China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China\u2019s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed\/refractory (r\/r) non-Hodgkin\u2019s lymphoma (nHL). This approval marks a significant step in InnoCare's efforts to expand its portfolio for hematological malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23464","og_locale":"en_US","og_type":"article","og_title":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23464","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-21T13:07:00+00:00","article_modified_time":"2025-01-27T13:10:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23464#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23464"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination","datePublished":"2022-12-21T13:07:00+00:00","dateModified":"2025-01-27T13:10:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23464"},"wordCount":364,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Boao Lecheng pilot zone","Cancer","HKG: 9969","Immunotherapy","InnoCare Pharma","SHA: 688428"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23464#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23464","url":"https:\/\/flcube.com\/?p=23464","name":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-21T13:07:00+00:00","dateModified":"2025-01-27T13:10:25+00:00","description":"China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China\u2019s Center for Drug Evaluation (CDE) to start a Phase II clinical trial assessing a combination of orelabrutinib with tafasitamab and lenalidomide in patients with relapsed\/refractory (r\/r) non-Hodgkin\u2019s lymphoma (nHL). This approval marks a significant step in InnoCare's efforts to expand its portfolio for hematological malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23464#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23464"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23464#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23464"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23464\/revisions"}],"predecessor-version":[{"id":23465,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23464\/revisions\/23465"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}